FDA'S DTC Task

In the weeks since the Food and Drug Administration told 23andMe that it must cease marketing its personal genome service there has been quite a bit of chatter about how the agency is being overly cautious, or too paternalistic, grinding up the gears of a fledgling industry while telling the American public that it knows better than them about what health information they can handle.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.